Neuraxis Inc - NRXS STOCK NEWS

Welcome to our dedicated page for Neuraxis news (Ticker: NRXS), a resource for investors and traders seeking the latest updates and insights on Neuraxis stock.

Neuraxis, Inc. (symbol: NRXS) is a growth-stage company pioneering in the development of neuromodulation therapies aimed at treating chronic and debilitating conditions in children. With a steadfast focus on disorders of gut-brain interaction (DGBIs), the company is committed to improving the lives of pediatric and adolescent populations. Neuraxis leverages its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology to deliver targeted therapies that are both innovative and effective.

In recent months, Neuraxis has made significant strides. Following its IPO, the company has successfully built a robust portfolio of research publications, which has enabled it to secure broad insurance policy coverage sooner than anticipated. This has led to increased revenues in regions such as Massachusetts and Wisconsin, where written policy coverage is in place.

As the company moves into 2024, it continues to focus on expanding insurance policy coverage, with 10 major meetings scheduled in the first quarter alone. Additionally, Neuraxis is preparing for the FDA clearance of a new pediatric IB-Stim indication by the end of 2024 and the introduction of a new RED product aimed at the adult gastrointestinal market, both expected to generate substantial revenue growth.

Financially, Neuraxis recently filed a restatement of its third-quarter 2023 financial results, resulting in a $3.7 million increase to the company's net loss and additional paid-in capital. However, this restatement is unrelated to revenues or cash expenses, and the company's cash position remains unchanged.

Looking ahead, Neuraxis is well-positioned for continued success. The company's dedicated team remains focused on advancing policy coverage, expanding its product pipeline, and preparing markets and children’s hospitals for effective treatments once coverage is in place.

For more detailed updates and to stay informed on the latest developments, shareholders and interested parties are encouraged to participate in the company’s upcoming first-quarter 2024 financial results conference call. Details for accessing the live webcast and replay are available on the company's Investor Relations website.